Lincoln Pharmaceuticals Limited (BOM:531633)
India · Delayed Price · Currency is INR 507.55
-5.55 (-1.08%)
At close: Nov 6, 2026
Lincoln Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 7,222 | 6,710 | 6,232 | 5,805 | 5,103 | 4,721 | |
Revenue Growth | 14.25% | 7.67% | 7.35% | 13.76% | 8.09% | 11.30% |
Cost of Revenue | 3,557 | 3,188 | 2,970 | 2,831 | 2,457 | 2,219 |
Gross Profit | 3,665 | 3,522 | 3,262 | 2,975 | 2,646 | 2,502 |
Selling, General & Admin | 1,341 | 1,316 | 1,179 | 1,074 | 981.38 | 845.1 |
Other Operating Expenses | 1,319 | 1,220 | 1,059 | 898.46 | 767.12 | 692 |
Operating Expenses | 2,812 | 2,681 | 2,371 | 2,079 | 1,840 | 1,625 |
Operating Income | 853.01 | 840.88 | 890.57 | 895.83 | 805.47 | 876.98 |
Interest Expense | -5.54 | -4.18 | -9.96 | -9.46 | -16.38 | -9.2 |
Interest & Investment Income | 79 | 79 | 73.1 | 70.28 | 61.71 | 50.28 |
Currency Exchange Gain (Loss) | 222.61 | 222.61 | 80.79 | 46.1 | 109.14 | 11.12 |
Other Non Operating Income (Expenses) | 110.12 | -2.83 | -2.06 | -5.19 | -3.92 | -4.6 |
EBT Excluding Unusual Items | 1,259 | 1,135 | 1,032 | 997.56 | 956.02 | 924.58 |
Gain (Loss) on Sale of Investments | 19.48 | 19.48 | 61.2 | 227.85 | 51.35 | 36.12 |
Gain (Loss) on Sale of Assets | 1.29 | 1.29 | -1.76 | -2.98 | -2.56 | -1.31 |
Pretax Income | 1,280 | 1,156 | 1,092 | 1,222 | 1,005 | 959.39 |
Income Tax Expense | 311.02 | 277.31 | 268.42 | 289.38 | 275.81 | 265.84 |
Earnings From Continuing Operations | 968.95 | 878.94 | 823.46 | 933.05 | 728.99 | 693.55 |
Net Income | 968.95 | 878.94 | 823.46 | 933.05 | 728.99 | 693.55 |
Net Income to Common | 968.95 | 878.94 | 823.46 | 933.05 | 728.99 | 693.55 |
Net Income Growth | 21.11% | 6.74% | -11.74% | 27.99% | 5.11% | 11.41% |
Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | 20 |
Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | 20 |
Shares Change | -0.01% | - | - | - | - | - |
EPS (Basic) | 48.38 | 43.88 | 41.11 | 46.58 | 36.40 | 34.63 |
EPS (Diluted) | 48.38 | 43.88 | 41.11 | 46.58 | 36.40 | 34.63 |
EPS Growth | 21.13% | 6.74% | -11.74% | 27.98% | 5.11% | 11.41% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 407.2 | 809.32 | 739.86 | 237.41 | 250.03 | 306.07 |
Free Cash Flow Per Share | 20.33 | 40.41 | 36.94 | 11.85 | 12.48 | 15.28 |
Dividend Per Share | 1.800 | 1.800 | 1.800 | 1.800 | 1.500 | 1.500 |
Dividend Growth | 0% | 0% | 0% | 20.00% | 0% | 0% |
Gross Margin | 50.74% | 52.49% | 52.34% | 51.24% | 51.84% | 52.99% |
Operating Margin | 11.81% | 12.53% | 14.29% | 15.43% | 15.78% | 18.57% |
Profit Margin | 13.42% | 13.10% | 13.21% | 16.07% | 14.29% | 14.69% |
Free Cash Flow Margin | 5.64% | 12.06% | 11.87% | 4.09% | 4.90% | 6.48% |
EBITDA | 1,003 | 984.33 | 1,018 | 1,001 | 895.8 | 956.29 |
EBITDA Margin | 13.89% | 14.67% | 16.34% | 17.24% | 17.55% | 20.26% |
D&A For EBITDA | 150.18 | 143.46 | 127.76 | 104.97 | 90.33 | 79.31 |
EBIT | 853.01 | 840.88 | 890.57 | 895.83 | 805.47 | 876.98 |
EBIT Margin | 11.81% | 12.53% | 14.29% | 15.43% | 15.78% | 18.57% |
Effective Tax Rate | 24.30% | 23.98% | 24.58% | 23.67% | 27.45% | 27.71% |
Revenue as Reported | 7,670 | 7,045 | 6,457 | 6,150 | 5,328 | 4,821 |
Advertising Expenses | - | 29.87 | 26.68 | 10.34 | 11.57 | 0.6 |